Efficacy, safety, and cost-effectiveness analysis of aflibercept in metastatic colorectal cancer: A rapid health technology assessment.

Ge, Pu; Wan, Ning; Han, Xiao; Wang, Xinpei; Zhang, Jinzi; Long, Xiaoyi; Wang, Xiaonan; Bian, Ying

Ge, Pu; Wan, Ning; Han, Xiao; Wang, Xinpei; Zhang, Jinzi; Long, Xiaoyi; Wang, Xiaonan; Bian, Ying.

Afiliação

Ge P; Institute of Chinese Medical Sciences, University of Macau, Macau, China.
Wan N; State Key Laboratory of Quality Research in Chinese Medicine, University of Macau, Macau, China.
Han X; Department of Public Health and Medicinal Administration, Faculty of Health Sciences, University of Macau, Macau, China.
Wang X; General Hospital of Southern Theater Command, Guangzhou, Guangdong, China.
Zhang J; Guangdong Branch Center, National Clinical Research Center for Geriatric Diseases (Chinese PLA General Hospital), Guangzhou, Guangdong, China.
Long X; School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.
Wang X; Institute of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom.
Bian Y; College of Humanities and Social Sciences, Harbin Medical University, Harbin, China.

Front Pharmacol ; 13: 914683, 2022.

Article em En | MEDLINE | ID: mdl-36110513

Palavras-chave

aflibercept; cost-effectiveness analysis; metastatic colorectal cancer; pharmacoeconomics; rapid health technology assessment; targeted drugs

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Health_technology_assessment / Prognostic_studies / Systematic_reviews Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google